MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Free Cash flow
-$21,354K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Proceeds from issuance of long-t...
Other (income) expense, net
Accrued expenses and other liabi...
Others
Negative Cash Flow Breakdown
Gain on change in fair value of ...
Research and development-Descart...
General and administrative
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Total revenues
0
78
947
1,850
Research and development-Legacy Selecta Programs
-
-
0
0
Research and development-Descartes08For MG
12,465
12,135
5,391
17,502
Research and development-Descartes08For Dermatomyositis
236
227
-
-
Research and development-Early Stage Programs
971
355
1,567
4,228
Research and development-Research And Development Employee Expenses
4,027
3,828
4,899
11,927
Research and development-Research And Development Share Based Payment Arrangement Expense
614
949
682
4,090
Research and development-Research And Development Facilities And Other Expenses
2,118
1,969
2,150
5,598
General and administrative
8,724
7,114
8,197
23,271
Impairment of indefinite-lived intangible and long-lived assets
-
-
56,700
-
Other expense (income), net
-
-
-
27,040
Other (income) expense, net
44,924
-12,683
13,103
-
Net loss
15,769
-39,182
-92,576
-35,902
Depreciation and amortization
779
615
608
606
Noncash lease expense
242
235
215
192
Loss on disposal of property and equipment
-
-
0
0
Impairment of indefinite-lived intangible and long-lived assets
-
-
56,700
-
Stockbased compensation expense
2,083
2,423
2,144
2,590
Noncash interest expense
355
-
-
-
Loss (gain) on change in fair value of warrant liability
118
-94
-707
-516
Loss on change in fair value of embedded derivative
4,535
-
-
-
Gain on change in fair value of contingent value rights liability
-49,200
13,800
23,100
16,900
Loss on change in fair value of forward contract liabilities
-
-
0
0
Loss on impairment of investment
-
-
2,000
-
(benefit) provision for deferred taxes
-
-
-9,193
-
Accounts receivable
-65
-854
393
368
Unbilled receivable
-
-
0
0
Prepaid expenses and other assets
-157
246
-264
438
Accounts payable
-773
310
-933
1,768
Deferred revenue
-
-
0
0
Accrued expenses and other liabilities
4,788
-850
1,059
-432
Net cash used in operating activities
-21,082
-22,135
-17,712
-15,600
Purchases of property and equipment
272
27
492
1,292
Proceeds from the sale of property and equipment
-
-
0
-
Proceeds from exercise of common warrants
-
-
0
0
Net cash used in investing activities
-272
-27
-492
-1,292
Proceeds from issuance of series a preferred stock, gross in private placement
-
-
0
0
Net proceeds from issuance of common stock and series b preferred stock in private placement
-
-
0
0
Proceeds from issuance of long-term debt, net
46,030
-
-
-
Equity offering costs
0
0
102
43
Proceeds from exercise of stock options
398
279
50
5
Proceeds from at the market offering, net of commissions and expenses
3,916
15,392
-
-
Distribution of contingent value rights
0
0
0
0
Net cash provided by (used in) financing activities
50,344
15,671
-52
-38
Effect of exchange rate changes on cash
-25
-7
11
-10
Net change in cash, cash equivalents, and restricted cash
28,965
-6,498
-18,245
-16,940
Cash and cash equivalents at beginning of period
120,376
126,874
145,119
214,279
Cash and cash equivalents at end of period
149,341
120,376
126,874
145,119
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Proceeds from issuance of
long-term debt, net
$46,030K
Proceeds from at the
market offering, net of...
$3,916K
Proceeds from exercise of
stock options
$398K
(48.51%↑ Y/Y)
Net cash provided by
(used in) financing...
$50,344K
(732.07%↑ Y/Y)
Other (income)
expense, net
$44,924K
Net change in cash,
cash equivalents,...
$28,965K
(155.47%↑ Y/Y)
Canceled cashflow
$21,379K
Net loss
$15,769K
(964.53%↑ Y/Y)
Accrued expenses and
other liabilities
$4,788K
(213.59%↑ Y/Y)
Loss on change in fair
value of embedded...
$4,535K
Stockbased compensation
expense
$2,083K
(-64.01%↓ Y/Y)
Depreciation and
amortization
$779K
(-55.36%↓ Y/Y)
Noncash interest
expense
$355K
Noncash lease expense
$242K
(-34.77%↓ Y/Y)
Prepaid expenses and
other assets
-$157K
(-103.06%↓ Y/Y)
Loss (gain) on change
in fair value of...
$118K
(104.77%↑ Y/Y)
Accounts receivable
-$65K
(87.45%↑ Y/Y)
Canceled cashflow
$29,155K
Net cash used in
operating activities
-$21,082K
(48.11%↑ Y/Y)
Net cash used in
investing activities
-$272K
(92.59%↑ Y/Y)
Effect of exchange rate
changes on cash
-$25K
(-156.82%↓ Y/Y)
Canceled cashflow
$28,891K
Research and
development-Descartes08For MG
$12,465K
General and
administrative
$8,724K
Research and
development-Research And Development...
$4,027K
Research and
development-Research And Development...
$2,118K
Research and
development-Early Stage Programs
$971K
Research and
development-Research And Development...
$614K
Research and
development-Descartes08For...
$236K
Gain on change in fair
value of contingent...
-$49,200K
(-38.02%↓ Y/Y)
Purchases of property and
equipment
$272K
(-92.59%↓ Y/Y)
Accounts payable
-$773K
(-434.63%↓ Y/Y)
Buy us a coffee
Cartesian Therapeutics, Inc. (RNAC)
Cartesian Therapeutics, Inc. (RNAC)